2,269 Shares in Thermo Fisher Scientific Inc. $TMO Acquired by NovaPoint Capital LLC

NovaPoint Capital LLC acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) in the 3rd quarter, Holdings Channel reports. The institutional investor acquired 2,269 shares of the medical research company’s stock, valued at approximately $1,101,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TMO. Brighton Jones LLC raised its stake in shares of Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after acquiring an additional 988 shares during the last quarter. Revolve Wealth Partners LLC increased its holdings in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares during the period. Vident Advisory LLC raised its position in Thermo Fisher Scientific by 23.5% during the 1st quarter. Vident Advisory LLC now owns 5,738 shares of the medical research company’s stock valued at $2,855,000 after purchasing an additional 1,092 shares during the last quarter. Brasada Capital Management LP purchased a new stake in Thermo Fisher Scientific in the 1st quarter worth approximately $4,505,000. Finally, Saudi Central Bank bought a new stake in shares of Thermo Fisher Scientific in the 1st quarter worth approximately $75,000. 89.23% of the stock is currently owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Michael D. Shafer sold 10,725 shares of the company’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $600.00, for a total value of $6,435,000.00. Following the transaction, the executive vice president owned 18,731 shares in the company, valued at $11,238,600. The trade was a 36.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Frederick M. Lowery sold 6,913 shares of the firm’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $597.68, for a total transaction of $4,131,761.84. Following the sale, the executive vice president owned 14,367 shares of the company’s stock, valued at approximately $8,586,868.56. This represents a 32.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 149,271 shares of company stock worth $86,507,282 over the last quarter. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.3%

Shares of NYSE TMO opened at $580.65 on Friday. The stock has a market cap of $218.16 billion, a P/E ratio of 33.54, a price-to-earnings-growth ratio of 4.12 and a beta of 0.90. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97. The firm has a 50-day moving average of $573.94 and a 200 day moving average of $503.50.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.50 by $0.29. The firm had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business’s revenue was up 4.9% on a year-over-year basis. During the same period last year, the business earned $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its board has authorized a stock buyback program on Thursday, November 6th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 2.4% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be issued a dividend of $0.43 per share. The ex-dividend date is Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.94%.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of research analyst reports. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. UBS Group upped their price objective on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a “neutral” rating in a report on Thursday, October 23rd. Barclays lifted their target price on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Hsbc Global Res raised shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Monday, December 1st. Finally, Citigroup upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $580.00 to $660.00 in a report on Thursday, December 11th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average target price of $616.60.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.